Cardiology Private Equity – Market Update

Fall 2025

SHARE

Overview

Cardiology is experiencing its own surge of private equity interest, with multiple physician practice management platforms, such as Cardiovascular Associates of America and StrideCare (Webster Equity Partners), US Heart and Vascular (Ares Management), and Cardiovascular Logistics (Lee Equity Partners), aggressively acquiring smaller groups and expanding market share. The cardiology sector is rapidly evolving into a competitive and consolidated landscape – mirroring trends seen earlier in other surgically driven specialties – while distinguishing itself through providing more control at the practice level to ensure patient care continues to be a top priority.

Bar chart showing transactions per quarter.

Source: Healthcare Dealflow


Following a significant wave of M&A activity between 2021 and 2023, the market has seen renewed momentum through the first half of 2025. The continued fragmentation of the cardiovascular sector is sustaining strong investor interest, and we expect cardiology to remain one of the most active areas within physician services M&A heading into 2026.

However, private equity backed cardiovascular buyers are increasingly targeting high-quality assets in select geographies, keeping competition and valuations elevated. Many private equity–backed cardiology groups are also approaching their “second bite” or recapitalization phase, injecting new capital to support ongoing acquisition strategies. At the same time, private equity firms continue to show strong interest in partnering with independent cardiology groups to establish new private equity backed cardiology platforms.

State-level regulations tied to the corporate practice of medicine continue to pose challenges for transactions, especially in California and Oregon. These hurdles are becoming more pronounced across additional states, as regulators continue to impose new limitations on healthcare investment.

It is essential that physician-owners seek appropriate guidance to navigate today’s complex dynamics.


Current Landscape of PE-Backed Platforms

Map showing cardiovascular private equity firms in the US.

Recent Cardiology & Vascular Transactions

Date TargetPE SponsorPlatform State
October 2025Vascular HealthAmulet Capital PartnersUnited Vein & Vascular CentersNJ
August 2025Vascular Institute of the RockiesAssured Healthcare PartnersHeart & Vascular PartnersCO
July 2025Coastal Vascular & Vein CenterWebster Equity PartnersStrideCareSC
June 2025Fort Worth Heart PartnersAres ManagementUS Heart & VascularTX
April 2025Cardiology Consultants of PhiladelphiaLee Equity Partners
Cardiovascular Logistics
PA
Nov 2024
Surgical Associates Chartered

Petra Capital / Canopy Capital

American Vascular Associates
MD
Oct 2024
Birmingham Heart Clinic
Ares ManagementUS Heart & VascularAL
July 2024*Florida Heart & Rhythm Specialists
Webster Equity Partners

Cardiovascular Associates of America
FL
July 2024*
Kenneth H. Zelnick, MD

Webster Equity Partners

Cardiovascular Associates of America
FL

*PGP Served as Exclusive Sell-Side Advisor to Practice Owners (Target)

About Our Firm

Physician Growth Partners (PGP) Physician Growth Partners (PGP) is an advisory firm working exclusively with independent physician groups in transactions with private equity.

PGP has completed 15+ transactions in the last 12 months. Our firm is differentiated by:

  • Senior partner involvement at every stage of the process
  • Extensive physician practice transaction experience
  • Unmatched relationships with all key private equity and strategic buyers interested in Cardiology
  • Educational approach focused on partnership and cultural fit + achieving a market-clearing valuation